Patents by Inventor Tetsuro Kikuchi

Tetsuro Kikuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11369883
    Abstract: A contribution degree calculation apparatus calculates a contribution degree of each of a plurality of players in a video game in which the plurality of players participate. The contribution degree calculation apparatus includes: a biological information obtainer configured to obtain biological information respectively corresponding to the plurality of players; a game data obtainer configured to obtain game data generated by the plurality of players playing the video game; a first calculator configured to calculate a first index related to a degree of an influence by one of the plurality of players to another player and a second index related to a mental load of the one player, from biological information corresponding to the one player; and a second calculator configured to calculate a contribution degree of the one player from the first index and the second index and from the game data.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: June 28, 2022
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Yasuo Katsuhara, Mirai Shimoyama, Hirotaka Kaji, Hirokazu Kikuchi, Nobuki Hayashi, Hiroki Ashizawa, Tetsuro Sakaguchi
  • Publication number: 20220000861
    Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.
    Type: Application
    Filed: March 10, 2021
    Publication date: January 6, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tsuyoshi HIROSE, Kenji MAEDA, Tetsuro KIKUCHI, Masafumi TODA
  • Publication number: 20210308126
    Abstract: The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbemazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, manta or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
    Type: Application
    Filed: November 4, 2020
    Publication date: October 7, 2021
    Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
  • Publication number: 20200405712
    Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
    Type: Application
    Filed: September 15, 2020
    Publication date: December 31, 2020
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Shaun Jordan, Tetsuro Kikuchi, Katsura Tottori, Tsuyoshi Hirose, Yasufumi Uwahodo
  • Publication number: 20200289501
    Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
    Type: Application
    Filed: October 28, 2019
    Publication date: September 17, 2020
    Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
  • Publication number: 20200246332
    Abstract: The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
    Type: Application
    Filed: September 20, 2019
    Publication date: August 6, 2020
    Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
  • Publication number: 20200093823
    Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
    Type: Application
    Filed: November 26, 2019
    Publication date: March 26, 2020
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Shaun Jordan, Tetsuro Kikuchi, Katsura Tottori, Tsuyoshi Hirose, Yasufumi Uwahodo
  • Publication number: 20190247324
    Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
    Type: Application
    Filed: October 2, 2018
    Publication date: August 15, 2019
    Inventors: Benjamin Whalley, Gary Stephens, Claire Williams, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
  • Publication number: 20190151308
    Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 23, 2019
    Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
  • Publication number: 20180344731
    Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
    Type: Application
    Filed: August 7, 2018
    Publication date: December 6, 2018
    Inventors: Shaun Jordan, Tetsuro Kikuchi, Katsura Tottori, Tsuyoshi Hirose, Yasufumi Uwahodo
  • Publication number: 20180325894
    Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents.
    Type: Application
    Filed: July 20, 2018
    Publication date: November 15, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tsuyoshi HIROSE, Kenji MAEDA, Tetsuro KIKUCHI, Masafumi TODA
  • Patent number: 10036479
    Abstract: A fusible plug employs an alloy which comprises 5-8 mass % of Sn, 31-34 mass % of Bi, 0.2-4 mass % of Sb, and a remainder of In. The alloy melts at approximately 66-70° C. The alloy may further contain at most 2.0 mass % of at least one element selected from strengthening elements consisting of 0.1-1.0 mass % of Cu, 0.1-1.0 mass % of Ge, 0.1-0.7 mass % of Ag, 0.1-0.6 mass % of Au, 0.2-0.6 mass % of Zn, 0.002-0.1 mass % of Ni, and 0.01-0.1 mass % of a lanthanoid.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: July 31, 2018
    Assignee: SENJU METAL INDUSTRY CO., LTD.
    Inventors: Rikiya Kato, Tetsuro Kikuchi, Mutsumi Deguchi, Yasuaki Koiwa
  • Patent number: 9895342
    Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: February 20, 2018
    Assignee: GW Pharma Limited
    Inventors: Sabatino Maione, Francesco Rossi, Geoffrey Guy, Colin Stott, Tetsuro Kikuchi
  • Publication number: 20180042923
    Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophea-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.
    Type: Application
    Filed: October 19, 2017
    Publication date: February 15, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tsuyoshi HIROSE, Kenji MAEDA, Tetsuro KIKUCHI, Masafumi TODA
  • Publication number: 20180042975
    Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
    Type: Application
    Filed: June 12, 2017
    Publication date: February 15, 2018
    Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Daniela Parolaro, Paola Massi, Angelo Antonio Izzo, Francesca Borrelli, Gabriella Aviello, Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello, Alessia Ligresti, Ruth Alexandra Ross, Lesley Ann Ford, Sharon Anavi-Goffer, Manuel Guzman, Guillermo Velasco, Mar Lorente, Sofia Torres, Tetsuro Kikuchi, Geoffrey Guy, Colin Stott, Stephen Wright, Alan Sutton, David Potter, Etienne De Meijer
  • Publication number: 20170273913
    Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
    Type: Application
    Filed: November 9, 2016
    Publication date: September 28, 2017
    Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Benjamin Whalley, Gary Stephens, Claire Williams, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
  • Publication number: 20170258788
    Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 14, 2017
    Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
  • Publication number: 20170224681
    Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
    Type: Application
    Filed: April 24, 2017
    Publication date: August 10, 2017
    Inventors: Shaun Jordan, Tetsuro Kikuchi, Katsura Tottori, Tsuyoshi Hirose, Yasufumi Uwahodo
  • Patent number: 9694009
    Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: July 4, 2017
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
  • Patent number: 9675654
    Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 13, 2017
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Daniela Parolaro, Paola Massi, Angelo Antonio Izzo, Francesca Borrelli, Gabriella Aviello, Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello, Alessia Ligresti, Ruth Alexandra Ross, Lesley Ann Ford, Sharon Anavi-Goffer, Manuel Guzman, Guillermo Velasco, Mar Lorente, Sofia Torres, Tetsuro Kikuchi, Geoffrey Guy, Colin Stott, Stephen Wright, Alan Sutton, David Potter, Etienne De Meijer